TITLE

S*BIO ADVANCES JAK2 INHIBITOR SB1518 INTO PHASE 1/2 TRIAL

PUB. DATE
January 2009
SOURCE
Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the initiation of a Phase � clinical trial of JAK2-selective kinase inhibitor drug SB1518 in patients with chronic idiopathic myelofibrosis (CIMF) in Australia in January 2009. The trial, launched by Singaporean company S*BIO Pte Ltd., will be conducted in two phases. Phase 1 will examine the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of the drug. While Phase 2 will explore the clinical benefits and safety profile of the drug. Also noted is the other drug pipeline product of S*BIO.
ACCESSION #
35859763

 

Related Articles

  • S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p1 

    The article reports that the clinical trial of the novel anti-cancer drug was initiated by the S*BIO Pte Ltd. in Singapore. The SB939 is a histone deacetylase (HDAC) inhibitor which is a targeted anti-cancer therapeutics. The SB939 Phase I trial was conducted to determine its pharmacokinetic and...

  • Pacritinib Reduces Splenomegaly in Myelofibrosis Patients.  // Drug Discovery & Development;Jan2012, Vol. 15 Issue 1, p26 

    The article discusses the Phase 2 study of S*BIO Pte. Ltd. on its JAK2 inhibitor pacritinib (SB1518) which indicates that pacritinib significantly reduces splenomegaly in patients with myelofibrosis.

  • Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. Anton Y. Peleg; Brian A. Potoski; Rhonda Rea; Jennifer Adams; Jigme Sethi; Blair Capitano; Shahid Husain; Eun J. Kwak; Sunil V. Bhat; David L. Paterson // Journal of Antimicrobial Chemotherapy (JAC);Jan2007, Vol. 59 Issue 1, p128 

    Objectives: Tigecycline has shown in vitro activity against Acinetobacter baumannii. Yet, published clinical experience with tigecycline use outside clinical trials is lacking. We describe, for the first time, bloodstream infection caused by tigecycline-non-susceptible A. baumannii occurring in...

  • Ruxolitinib In the Treatment of Myelofibrosis. Yang, Lily P. H.; Keating, Gillian M. // Drugs;2012, Vol. 72 Issue 16, p2117 

    Ruxolitinib is a selective inhibitor of Janus kinases (JAK) 1 and 2, which are involved in the signalling pathway of various cytokines and growth factors essential to haematopoiesis. JAK 1 and 2 are implicated in the development of myelofibrosis, as well as other haematological malignancies....

  • A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Mesa, R. A.; Camoriano, J. K.; Geyer, S. M.; Wu, W.; Kaufmann, S. H.; Rivera, C. E.; Erlichman, C.; Wright, J.; Pardanani, A.; Lasho, T.; Finke, C.; Li, C. Y.; Tefferi, A. // Leukemia (08876924);Sep2007, Vol. 21 Issue 9, p1964 

    Patients with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) have limited therapeutic options. The farnesyltransferase-inhibitor tipifarnib inhibits in vitro proliferation of myeloid progenitors from such patients. In the...

  • CLINIC ROUNDUP.  // BioWorld Today;9/19/2008, Vol. 19 Issue 183, p7 

    This section offers news briefs on the pharmaceutical industry. Avigen Inc. has completed the double-blind portion of its Phase IIb trial for AV650 used in the treatment of spasticity linked to multiple sclerosis. Positive results were reported by Incyte Corp. from Phase IIa trials of topical...

  • Singapore's S*BIO Adds $26M for Phase II Studies in Cancer. Hollingsworth, Catherine // BioWorld Today;10/21/2008, Vol. 19 Issue 205, p1 

    The article reports that S*BIO Pte. Ltd. has raised $26 million to fund phase II trials for the SB939 and SB1518 cancer drugs in 2008. The financing was led by Bio*One Capital, a member of the Singapore Economic Development Authority and Aravis Venture. In a statement, chief executive Jan Anders...

  • Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments. Ogungbenro, Kayode; Aarons, Leon // Journal of Pharmacokinetics & Pharmacodynamics;Aug2011, Vol. 38 Issue 4, p449 

    In the recent years, interest in the application of experimental design theory to population pharmacokinetic (PK) and pharmacodynamic (PD) experiments has increased. The aim is to improve the efficiency and the precision with which parameters are estimated during data analysis and sometimes to...

  • Fosfomycin: an old, new friend? Popovic, M.; Steinort, D.; Pillai, S.; Joukhadar, C. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2010, Vol. 29 Issue 2, p127 

    Fosfomycin (FOM) is an antibiotic which has varying application indications across the globe. European, Japanese, South African and Brazilian usage practices are much broader, involving multiple formulations of FOM than the currently limited application of FOM in the United States, where...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics